Dr. Monika Hupfauf

INDUSTRY FOCUS:

Comprehensive accompanying legal advice
/   in the development of pharmaceuticals and medical devices up to market launch
/   of technology companies in connection with research and development projects
/   research centers and consortia

AREAS OF EXPERTISE:

INTELLECTUAL PROPERTY LAW AND COMMERCIAL LEGAL PROTECTION

MEDICINAL PRODUCT AND MEDICAL PRODUCT

R & D, TECHNOLOGY TRANSFER

IT LAW / DATA PROTECTION

ALTERNATIVE DISPUTE RESOLUTION AND ECONOMIC MEDIATION

EXPERIENCE: 

1999/2000: Diploma Cardiff University, Wales   ///   2001: University of Innsbruck – Mag. iur.   ///   2006: University of Innsbruck – Dr. iur.   ///  2008: Attorney’s examination OLG Vienna   ///   2008: Degree Falk Business Mediation – Registered Business Mediator at WIPO   ///   2011 Judge’s Admission OLG Innsbruck /// Attorney at law and trainee lawyer in national and international law firms Professional experience in a patent law firm and a cancer research center 

LANGUAGES:

German and English

CURRENT LABOR / PUBLICATIONS:

University of Innsbruck, Pharmig Academy, European QP Association, Austrian QP Association, WIPO, Pharma Law Convention, World IP Day, AWS, FFG   Cloud Migration (co-author); Tobias Höllwarth (ed.) 2012   Only weak antidote to counterfeit medicines; The standard 08.02.2016  Setback by DDoS: The data bomb as an emergency measure; The standard 24.07.2016

Peter Homberg

Peter Homberg is a partner in the Dentons Frankfurt office. He specializes in IP, corporate law and M&A transactions in the life sciences and high-tech sector as well as in R&D and cooperation agreements, cross-border IP licensing and IP strategies. Peter advises inter alia companies in the pharmaceutical, diagnostics, biotechnology and medical device industry – from startups to large publicly listed companies. Furthermore, he has broad transactional experience in Southeast Asia. Peter is member of the Licensing Executive Society (LES), the German Association for Intellectual Property and Copyright (GRUR), the German Institution for Arbitration (DIS) as well as the Pharma-Lizenz-Club Deutschland e.V. He regularly holds lectures at seminars and conferences, and is also author of numerous professional articles and other publications regarding corporate or IP law in the field of life sciences.

Experience:

  • Scil Technology GmbH: Advising regarding the out-licensing of certain intellectual property for the regenerative treatment of inter alia Osteoarthritis to Sanofi.
  • Scil Technology GmbH: Advising regarding the sale of its service and production division to Nanohale AG.
  • German biotechnology company: Advising regarding the sale of a certain IP-portfolio for the treatment of cardiac insufficiency.
  • German mid-size pharmaceutical company: Advising regarding the licensing and distribution of a certain API for the treatment of interstitial cystitis to a multinational US-based pharmaceutical company.
  • US-based pharmaceutical enterprise: Advising regarding the due diligence in connection with a certain technology portfolio for the manufacturing of vaccines prior to the in-licensing of the technology.
  • Swiss-based biotechnology company: Advising regarding cooperation with a French multinational pharmaceutical enterprise.
  • Priaxon AG: Advising regarding the out-licensing of a certain technology to Boehringer Ingelheim.
  • German-Singaporean biotech company: Advising regarding the in-licensing of a certain diagnostic technology from the National University of Singapore.
  • French venture capital fund: Advising regarding the acquisition of shares in a German-based biotechnology company.
  • German medium-size pharmaceutical company: Advising regarding the restructuring of its distribution channels in Portugal and in other European countries.
  • Various clients in the life sciences sector: Advising in all types of transactions, including technology transfer agreements, R&D agreements, M&A transactions, private equity transactions, arbitration proceedings and litigations.

Recognition:

Peter Homberg is highlighted by Chambers Europe, 2014 as “a brilliant negotiator”, who “has huge experience with biotech companies and is really goal driven. He understands our needs very well.” JUVE Handbook German Commercial Law Firms, 2015/2016 mentions Peter Homberg as a highly recommended practitioner. The international directory Best Lawyers ranked him among the best lawyers for Health Care Law and Pharmaceuticals Law in Germany. Global Law Experts honor Peter Homberg as “Life Sciences Lawyer of the Year in Germany”.

Articles:

  • „Crowdfunding für Biotech-Firmen“, transkript, May 2017
  • „Zulassungsfragen bei Produkten der personalisierten Medizin – Das rechtliche Umfeld von Companion Diagnostics“, „Transparenz / Neue Produkte“ von Wolfgang Voit (Hrsg.), Marburger Schriften zum Gesundheitswesen, 18. Marburger Gespräche, Nomos Verlag, 2017
  • Co-author, „Aufgaben und Inhalt des (virtuellen) Datenraums“, transkript, 2016
  • “Korruption im Gesundheitswesen“, Science4Life, 2016
  • Co-author, “Biotechnologie und Big Pharma – Erfolgsfaktoren beim Exit“, Biotechnologie, 2016
  • Co-author, “Korruption im Gesundheitswesen”, transkript, 2016
  • “The “Safe Harbor” judgment of the European Court of Justice (“ECJ”)  – Practical impacts,” Expert Guide, Biotechnology & Pharmaceuticals 2016, 2015
  • Co-author, “Big Pharma und Biotech  – Das Ende der Einlizenzierungswelle?,” Going Public – Health, 2015
  • Co-author, “Neuer Vorstoß zur Bekämpfung der Korruption im Gesundheitswesen,“ Science4Life September 2015, 2015
  • Co-author, “Auftragsforschung – Zu welchem Preis?,“ GoingPublic Magazin – Special „Biotechnologie 2015“, 2015
  • Co-author, “Wettbewerbsbeschränkungen im Technologietransfer, Patentkommentar,” transkript, 2015
  • Co-author, “Bekämpfung von Korruption im Gesundheitswesen,” Risk, Fraud & Compliance, 2015
  • Co-author, “Transparency vs protection of business secrets,” European Biotechnology News, 2015
  • Co-author, “Auslizenzierungspraxis von Universitäten,” Platow Recht, 2014
  • “Das europäische Einheitspatent,” Science4Life, 2014
  • Co-author, “IP Flash – The new TTBER: Changes of Termination Clauses,” Euro Biotech News, 2014
  • Co-author, “Die neue GVO-TT – Überblick und Auswirkungen, Technologietransfer,” transkript, 2014
  • Co-author, “‘One-Size-fits-All‘ zur maßgeschneiderten Therapie, Rechtliche Harmonisierungsbemühungen im Bereich der personalisierten Medizin,” GoingPublic Life Sciences, 2014
  • “Umfüllen eines Arzneimittels erneut genehmigungsbedürftig?,” pharmind, 2013
  • Co-author, “Fernabsatzverträge für Arzneimittel, Retoure: Verbraucherschutz vor Arzneimittelsicherheit?,” transkript, 2013
  • Co-author, “The impact of the new TTBER,” BIO – Europe, 2013
  • Co-author, “Transparenz versus Schutz von Geschäftsgeheimnissen – Neuer Entwurf einer EU-Verordnung für klinische Prüfungen,” GoingPublic Magazin – Special „Biotechnology 2013″, 2013
  • “Konfliktpotentiale minimieren,” IHK WirtschaftsForum, 2013
  • Co-author, “Das rechtliche Umfeld bei Companion Diagnostics,“ Venture Capital Special “Personalisierte Medizin”, 2013
  • “Forschung und Entwicklung,“ IHK WirtschaftsForum, 2013
  • “Umfüllen eines Arzneimittels erneut genehmigungsbedürftig?,“ Pharmind, 2013
  • “Out-licensing in the life sciences sector,” IP-Special, European Biotechnology News, 2013
  • “Cooperation agreements in the field of Industrial Biotechnology, The clever use of contract models,” GoingPublic, Special “Industrial Biotechnology”, 2013
  • “Erleichterung in der Medizintechnik, Gesetzliche Lockerungen in der Werbung für Medizinprodukte in Kraft getreten,“ GoingPublic, Special “Medizintechnik“, 2012
  • “Real cooperation – at an early stage,” European Biotechnology Science & Industry News, 2012
  • “Klinische Prüfungen mit Humanarzneimitteln,“ transkript, 2012
  • “Mittelständische Pharmaunternehmen als strategische Investoren in der Frühphase, Neue Dealstrukturen für Kooperationen zwischen mittelständischen Pharma- und Biotechnologieunternehmen,“ GoingPublic, Special “Biotechnologie“, 2012
  • “Das ergänzende Schutzzertifikat, Aktuelle Entscheidungen des Europäischen Gerichtshofs zur Verlängerung der Exklusivität bei pharmazeutischen Produkten,“ GoingPublic, 2012
  • “Komplette branchenspezifische Life Sciences-Beratung,“ Venture Capital Magazin, 2012
  • “Lizenzen in der Insolvenz,“ Deutscher AnwaltSpiegel, 2012
  • “Rechtliche Rahmenbedingungen beim Einsatz von Biomarkern in Europa,“ Venture Capital Magazin, 2012
  • “‘Zweiter Versuch‘, Der aktuelle Referentenentwurf des BMJ zur Insolvenzfestigkeit von Lizenzen,“ Deutscher AnwaltSpiegel, 2012
  • “Insolvenzfestigkeit von Lizenzen,“ transkript, 2012
  • “Lizenzverträge – eine juristische Herausforderung,“ transkript, Special BIO-Europe, 2011
  • “Licensing Projects in the Pharmaceutical Industry from a Legal Perspective,” European Biotechnology News, 2011
  • “Alternative Streitbeilegung im Laborgerätesektor,“ transkript, Special „Biotechnica“, 2011
  • “Biosimilars – hohe Hürden bis zur Zulassung,“ transkript, 2011
  • “Korruptionsprävention in der Pharmaindustrie – unter besonderer Fokussierung auf den Arzneimittelmarkt,“ Forum juris, 2011
  • “Markttrend Lizenztransaktionen: Ausgewählte rechtliche Aspekte,“ GoingPublic, Special “Biotechnologie“, 2011
  • “Weigerung der Mitgesellschafter zur Mitwirkung an einer den Verkaufsprozess vorbereitenden Due Diligence,“ Forum juris, 2011
  • “Grenzen der Heilmittelwerbung – Möglichkeiten der Vermarktung von Medizintechnik- und Medizinprodukten,“ Forum juris, 2011
  • “Alternative Streitbeilegung bei Lizenzverträgen – Gestaltungsmöglichkeiten bei Schiedsklauseln,“ Forum juris, 2011
  • “Companion Diagnostics – neue rechtliche Herausforderungen,“ transkript, 2011
  • “Functional Food oder Arzneimittel”, GoingPublic, Special “Healthcare”, 2011
  • “Pharma und Social Media,” commentary, PR Report, 2011
  • “Digitale Patientenkommunikation – juristische Perspektiven,” Pharma Marketing Journal, Healthcare Marketing, Pharma Relations, 2010
  • “EU-Kartellwächter behalten Pharmabranche im Visier,“ Handelsblatt, 2010
  • “Kommando Machtübernahme,“ commentary, zenith-BusinessReport, 2010
  • “Alternative Streitbeilegung,“ GoingPublic, Special “Biotechnologie“, 2010
  • “Gestaltungsmöglichkeiten bei Schiedsklauseln,“ GoingPublic, Special “Biotechnologie“, 2010
  • “Apotheken dürfen nur kleine Boni geben,“ commentary, Handelsblatt, 2010
  • “Apotheken ringen um Kundenrabatte,“ commentary, Wirtschaftswoche, 2010
  • “Commentary, Biotech-IPO-Sentiment,” GoingPublic, Special „Biotechnologie“, 2010
  • “Gewerbliche Schutzrechte sichern,“ IHK WirtschaftsForum, 2010
  • “Zu Risiken und Rabatten fragen Sie Ihren Arzt oder Apotheker,“ commentary, Handelsblatt, 2010
  • “A potentially nasty trap for licensees,” European Biotechnology News, 2010
  • “Auslizenzierung an Pharmaunternehmen als Finanzierungsinstrument,“ Venture Capital Magazin Special Tech-Guide, 2010
  • “Wer hat Anspruch auf die Erfindung? Das deutsche Arbeitnehmerfindergesetz und seine Novellierung im Jahr 2009,“ GoingPublic, 2010
  • “Vertragssicherheit im Falle von Insolvenz oder Kündigung,“ transkript, 2010
  • “Stammzellforschung – eine Analyse der gegenwärtigen Rechtslage und ihrer praktischen Umsetzung,“ Forum juris, 2010
  • “Investitionsanreize in der Weißen Biotechnologie,“ GoingPublic, Special Weiße Biotechnologie, 2010

Books:

  • “Pharma und Life Sciences“, Vertragshandbuch, Verlag C.H. Beck, 2015

Interviews:

  • ”Anwalts neuer Liebling,” transkript, published 2016
  • “Weltweit stark aufgestellt,“ transkript, published 2013
  • “EU rules for better access to finance,” Euro Biotech News, Special „Biocapital”, published 2013
  • “Aller guten Dinge sind drei,“ transkript, published 2013
  • “Keine Rabatte auf deutsche Rezepte,“ Handelsblatt, published 2012
  • “Nichts für Konfliktscheue,“ WirtschaftsWoche, published 2012
  • “Wikipedia ist die am stärksten genutzte Ärzte-Website (Chancen und Risiken in der digitalen Kommunikation),“ pharma marketing e-journal, published 2012

Presentations:

Peter regularly holds lectures at seminars and conferences, among others, at the Management Circle (e.g. “IP-Stipulations in cooperation agreements”) or the Marketing Conference of Medical Technology (e.g. “Update on Therapeutic Products Advertising – Latest Law on Marketing of Medical Technology and Medical Devices on the Basis of Case Studies”).

Memberships:

  • Member, Licensing Executive Society (LES)
  • Member, German Association for Intellectual Property and Copyright (GRUR)
  • Member, German Institution for Arbitration (DIS)
  • Member, Pharma-Lizenz-Club Deutschland e.V.

Prior and Present Employment:

  • Partner, Dentons (formerly Salans), Frankfurt, 2012 to date
  • Partner, (Head of German Life Sciences Practice) Raupach & Wollert-Elmendorff, Frankfurt, 2010-2012
  • Partner, Jones Day (Head of German and European Life Sciences Practice and Intellectual Property Practice), Frankfurt, 2001-2009
  • Deputy Head of Legal Department, Roche Diagnostics GmbH, Mannheim, 1996-2001
  • Head of the investment projects department, Debis Marketing Services, 1994-1996
  • Head of Singapore office, Thümmel Schütze & Partner, Singapore, 1990-1994
  • In-house Counsel, C. Wuppesahl Insurance Brokers, 1989-1990

Dimpy Mohanty

Dimpy is Partner at LexCounsel and has over fifteen years of experience advising and representing clients on Employment law as well as General Corporate & Commercial law, Education, Media, Real Estate, Life Sciences, Insurance and Regulatory law matters.

Her expertise in the field of employment law includes: Non-solicitation, employee claims including for bonus, stock option and other incentive schemes, downsizing, enforcement of employee post termination obligations and strategies for containing attrition, paternity leave policy, issues related to secondment, work visas.

EDUCATION:
  • LL.B. in 1999 from University of Delhi
  • B.A. (Hons) Psychology in 1994 from Lady Shri Ram College for Women, University of Delhi
MEMBERSHIPS:
  • Bar Council of Delhi, Bar Association of Delhi and International Bar Association.
LANGUAGES:
  • English, Hindi & Oriya.

The Employment Law Practice:

Professionals of LexCounsel have over the years advised many Indian and foreign businesses on aspects of employment laws, compliances and strategies including:

  • Employment, retainer, consultancy and advisory contracts, employee manuals, policies and benefit schemes and recruitment strategies;
  • Attrition issues, pre and post termination restrictive covenants and enforcement of post termination confidential, non-disclosure and non-solicitation obligations and protection of trade secrets;
  • Closure of businesses, settlement of employee dues, good-faith placement assistance, transfer of divisions with continuity of service and employment benefits;
  • Termination strategies, non-discrimination requirements, downsizing, workmen insurance and compensation, voluntary separation schemes, payment of retrenchment/termination compensation and benefits for employees;
  • Collective bargaining and negotiations with trade unions;
  • Conduct of industrial disputes, statutory registrations and certifications;
  • Dealing with tortious interference with employment and customer contracts, and employers vicarious liability issues;
  • Statutory registrations and certifications and labour law audits in view of different state specific regulations concerning leave, termination notice, right of recovery of training expenses, hours of work, etc.;
  • Agreements for outsourcing of workforce in information technology, insurance and security services and manpower services agreements for office support staff on an all India basis;
  • Representations, advises, replies to notices, calculation of statutory deductions and supervising compliances for clients in the outsourcing industry;
  • Engagement of child artists and differently abled individuals; and
  • Engagement of expatriates, relocation issues, tax issues and local assistance.

LexCounsel:

LexCounsel is a New Delhi based law firm established to provide superior quality, knowledge based, effective, business oriented legal services to its clients. Founded on best international practices, coupled with strong capabilities and experience of its members, LexCounsel provides comprehensive legal services and solutions to a broad spectrum of domestic and foreign clients, ranging from start-up companies to multinational corporations.

Our members have substantial expertise in their practice areas and in-depth sector specific understanding and knowledge to provide customized and highly effective legal advise best suited to the clients’ business needs, be it simple or complex multiparty transaction. In recognition, partners of the Firm have been consistently nominated Leading Lawyers in their respective areas of practice, particularly in IT, telecommunications and media; venture capital and private equity; and labour and employment. Our members add real value for clients in the way they achieve objectives and resolve complex legal issues. Our members are known to be uncompromising when it comes to professional standards, quality of advise and responsiveness.

The Firm is equipped with advanced technologies, management resources, updated library systems and other dedicated support systems to ensure timely delivery of legal services.

With a close network of associate offices in Mumbai, Bengaluru, Kolkata, Hyderabad, Chennai, Pune and Goa, LexCounsel draws on the specialized expertise of several professionals and specialists to provide seamless and complete legal business advise throughout India.